CDA | Evidence Driven
CDA | Evidence Driven

Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Export to CSV
Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Myalepta metreleptin Leptin deficiency in lipodystrophy Active
Adtralza tralokinumab atopic dermatitis (AD) Active
Repatha evolocumab Primary hyperlipidemia Active
TBC sotatercept Pulmonary arterial hypertension (WHO group 1) Active
Tecvayli teclistamab Relapsed or refractory multiple myeloma Reimburse with clinical criteria and/or conditions Active
Remsima infliximab Crohn’s disease Active
Remsima infliximab Ulcerative Colitis Active
TBC eplontersen Polyneuropathy in hereditary transthyretin-mediated amyloidosis Active
Jemperli dostarlimab Endometrial cancer Active
Libtayo cemiplimab Locally advanced or metastatic NSCLC (first line) Active
Last Updated : May 2, 2024